跳至主要内容
临床试验/NL-OMON53030
NL-OMON53030已完成不适用

Development of a platform for next-generation DNA sequencing based personalized treatment for cancer patients: Protocol to obtain biopsies from patients with locally advanced or metastatic cancer. - CPCT - 02 biopsy protocol

Radboud Universitair Medisch Centrum0 个研究点目标入组 7,500 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
7,500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 64(—)

入选标准

  • * Patient with the following locally advanced or metastatic cancer for whom a
  • new line of therapy is indicated starting within 3 months after biopsy:
  • - Metastatic Pancreas Cancer: FOLFIRINOX (Folinic acid [leucovorin] +
  • Fluorouracil [5-FU] + Irinotecan + Oxaliplatin)
  • - Metastatic Bladder Cancer (including Renal Cell Cancer and all types of
  • Urothelial Cell Cancer): Pembrolizumab
  • * Measurable metastatic or locally advanced lesion(s), according to RECIST 1.1
  • criteria.. Guidelines for response evaluation are given in appendix A.
  • * Metastatic or locally advanced lesion(s) of which a histological biopsy can
  • safely be obtained.
  • * Patients age > 18 years, willing and able to comply with the protocol as
  • judged by the investigator with a signed informed consent.
  • Patients must meet selection criteria 3 not only prior to baseline biopsy, but
  • also prior to the (optional and if applicable, see CPCT-02 Study manual)
  • post-treatment biopsies.

排除标准

  • No locally advanced or metastatic cancer.
  • Age below 18 years

研究者

相似试验